Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages 1326-1336

  Kim, Edward S ^a   Neubauer, Marcus ^b,c   Cohn, Allen ^c,d   Schwartzberg, Lee ^e   Garbo, Lawrence ^c,f   Caton, John ^c,g   Robert, Francisco ^h   Reynolds, Craig ^c,i   Katz, Terry ^j   Chittoor, Sreeni ^c,k   Simms, Lorinda ^l   Saxman, Scott ^l  

^a LEVINE CANCER INSTITUTE   (United States)

^b Kansas City Cancer Center   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d Rocky Mountain Cancer Center   (United States)

^e West Clinic   (United States)

^f New York Oncology Hematology   (United States)

^g Willamette Valley Cancer Center   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ Ocala Oncology Center   (United States)

^j ImClone Systems LLC   (United States)

^k TEXAS ONCOLOGY   (United States)

^l ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; PEMETREXED; PLATINUM COMPLEX;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANADA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; COMPARATIVE EFFECTIVENESS; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CYST; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG FATALITY; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; INFECTION; INFESTATION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; LEUKOCYTE; LEUKOCYTE COUNT; LOADING DRUG DOSE; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; POLYP; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SEPSIS; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SURVIVAL RATE; THORAX DISEASE; THORAX PAIN; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNITED STATES; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; TAXOIDS; TREATMENT FAILURE; UNITED STATES;

EID: 84888129994     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70473-X     Document Type: Article

References (31)

1. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:430-440.
2. Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2007, 2:402-407.
3. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000, 18:2354-2362.
4. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
7. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
8. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005, 11:795-805.
9. Kim ES, Mauer AM, William WN, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009, 115:1713-1722.
10. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
11. Common terminology criteria for adverse events v3.0 (CTCAE) National Cancer Institute, (accessed July 30, 2013). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
12. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
13. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
15. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
16. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
18. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
19. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell-lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
20. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
21. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
22. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
23. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
24. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
25. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
26. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, 13:539-548.
27. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009, 101:1308-1324.
28. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:918-927.
29. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011, 12:795-805.
30. Lynch T, Bhagavatheeswaran P, Mukhopadhyay P, Khambata-Ford S, Harbison CT A retrospective subgroup analysis of EGFR immunohistochemistry (IHC) expression by histo-score correlated to outcomes from the BMS099 1st line phase III NSCLC trial of cetuximab (cet) plus carboplatin/taxane. Eur J Cancer 2011, 47(suppl 1):S591-S592.
31. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012, 18:4004-4012.